$98.27
0.46% yesterday
Nasdaq, Sep 23, 10:00 pm CET
ISIN
US09075V1026
Symbol
BNTX

BioNTech SE - ADR Stock price

$98.27
-6.80 6.47% 1M
-2.37 2.35% 6M
-15.68 13.76% YTD
-14.78 13.07% 1Y
-30.08 23.44% 3Y
+35.28 56.02% 5Y
+84.22 599.33% 10Y
+84.22 599.33% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.45 0.46%
ISIN
US09075V1026
Symbol
BNTX
Industry

Key metrics

Basic
Market capitalization
$23.7b
Enterprise Value
$7.5b
Net debt
positive
Cash
$16.6b
Shares outstanding
240.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.0 | 9.3
EV/Sales
2.2 | 2.9
EV/FCF
negative
P/B
1.1
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$3.4b | $2.6b
EBITDA
$-462.4m | $-2.0b
EBIT
$-821.4m | $-1.9b
Net Income
$-408.1m | $-1.4b
Free Cash Flow
$-3.0b
Growth (TTM | estimate)
Revenue
7.0% | -21.1%
EBITDA
25.4% | -95.8%
EBIT
5.2% | -36.2%
Net Income
31.5% | -80.8%
Free Cash Flow
-208.7%
Margin (TTM | estimate)
Gross
84.2%
EBITDA
-13.6% | -77.7%
EBIT
-24.2%
Net
-12.0% | -55.4%
Free Cash Flow
-88.9%
Financial Health
Equity Ratio
86.2%
Return on Equity
-3.4%
ROCE
-3.5%
ROIC
-10.6%
Debt/Equity
0.0
More
EPS
$-1.7
FCF per Share
$-12.6
Short interest
6.5%
Employees
7k
Rev per Employee
$480.0k
Show more

Is BioNTech SE - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

BioNTech SE - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a BioNTech SE - ADR forecast:

21x Buy
75%
7x Hold
25%

Analyst Opinions

28 Analysts have issued a BioNTech SE - ADR forecast:

Buy
75%
Hold
25%

Financial data from BioNTech SE - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,401 3,401
7% 7%
100%
- Direct Costs 539 539
15% 15%
16%
2,862 2,862
6% 6%
84%
- Selling and Administrative Expenses 639 639
10% 10%
19%
- Research and Development Expense - -
-
-
-462 -462
25% 25%
-14%
- Depreciation and Amortization 359 359
46% 46%
11%
EBIT (Operating Income) EBIT -821 -821
5% 5%
-24%
Net Profit -408 -408
32% 32%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about BioNTech SE - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioNTech SE - ADR Stock News

Neutral
GlobeNewsWire
about 23 hours ago
MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host its second AI Day, an edition of BioNTech's “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Wednesday, October 1, 2025, in London, United Kingdom. The event will provide an overview of BioNTech's AI...
Positive
The Motley Fool
one day ago
A victory on the regulatory front and a bullish analyst move were the twin news items propelling BioNTech's (BNTX 2.52%) shares higher as the stock trading week began on Monday. The Germany-based biotech's equity rose by almost 3% in value during the session, comparing well to the 0.4% improvement of the S&P 500 index.
Neutral
Investors Business Daily
6 days ago
The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters from Pfizer, Moderna and Novavax.
More BioNTech SE - ADR News

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.

Head office Germany
CEO Ugur Sahin
Employees 6,772
Founded 2008
Website www.biontech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today